The Oxford Science Park

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

Oxford BioTherapeutics announces strategic collaboration with GSK

12 Dec 2025

Oxford BioTherapeutics (OBT), a clinical stage oncology company based at The Oxford Science Park, today announced a multi-year, multi-target strategic collaboration with GSK to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer. OBT's recently enhanced proprietary OGAP®-Verify discovery platform enables highly sensitive identification of oncology targets with improved attributes for drug... Read more

EIT-funded Generative Biology Doctoral Training Programme launches at Oxford University

10 Dec 2025

The University of Oxford, in partnership with the Ellison Institute of Technology (EIT), plans to launch the Generative Biology Doctoral Training Programme (DTP) - a four-year DPhil designed to allow the next generation of researchers to explore how to synthesize the DNA sequences of organisms to program and engineer biology. Fully funded by EIT, the programme will be hosted by Oxford’s Department of Chemistry and involves academics from... Read more

New CEO for Oxford Nanopore Technologies

09 Dec 2025

Oxford Nanopore Technologies has announced the appointment of Francis Van Parys as Chief Executive Officer. Francis will join the company and the Board as an Executive Director on 2 March 2026. Francis brings more than 20 years of experience leading multi-billion-dollar life science businesses, with a strong track record of scaling innovation-driven organisations through commercial and operational excellence. He is currently President and CEO... Read more

Scripta Therapeutics raises $12M to find disease-modifying drugs that alter transcription factor activity

13 Nov 2025

Scripta Therapeutics, based at The Oxford Science Park, has emerged from stealth by announcing a $12 million seed round to upend conventional approaches to drug discovery. Scripta combines AI, imaging, and patient-derived models to create and modulate disease maps based on transcriptional networks, building a new biology-first paradigm to decode and undo the programs that drive disease. The round is led jointly by Oxford Science... Read more

Enara Bio announces discovery of new cancer specific dark antigen

06 Nov 2025

Enara Bio has identified a new cancer-specific marker, called DARKFOX, that the company says could broaden the reach of next-generation immunotherapies for solid tumours. DARKFOX is a protein fragment displayed on the surface of many solid tumour cells - including most lung, head and neck, and oesophageal squamous cell cancers - while appearing at very low levels in healthy tissue. According to Enara, this combination of broad tumour coverage... Read more

News